Evidence map›Paper›PMID 40589639›Full record

ReviewFrontiers in oncology2025

Photodynamic therapy and nanomedicine: current knowledge, limitations, and applications in oral squamous cell carcinoma: a narrative review.

Fariba Esperouz, Mauro Lorusso, Andrea Santarelli, Alfredo De Lillo, Lorenzo Lo Muzio, Domenico Ciavarella, Lucio Lo Russo

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fariba EsperouzDepartment of Clinical and Experimental Sciences, University of Foggia, Foggia, Italy.
Mauro LorussoDepartment of Clinical and Experimental Sciences, University of Foggia, Foggia, Italy.
Andrea SantarelliDepartment of Clinic Specialistic and Stomatological Sciences, Polytechnic University of Marche, Ancona, Italy.
Alfredo De LilloDepartment of Clinical and Experimental Sciences, University of Foggia, Foggia, Italy.
Lorenzo Lo MuzioDepartment of Clinical and Experimental Sciences, University of Foggia, Foggia, Italy.
Domenico CiavarellaDepartment of Clinical and Experimental Sciences, University of Foggia, Foggia, Italy.
Lucio Lo RussoDepartment of Clinical and Experimental Sciences, University of Foggia, Foggia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral squamous cell carcinoma is still a global health issue, even if oral cavity is an easily accessible anatomical site, the diagnosis is still delayed. Conventional treatments, like chemotherapy and radiotherapy, are usually employed, but not without complications. These drawbacks have necessitated the need for new therapies, one of these is photodynamic therapy (PDT). Nanotechnologies-enhanced PDT has significantly improved tumor targeting, bioavailability, and light absorption, paving the way for its application in early-stage of oral squamous cell carcinoma (OSCC) and as part of combination therapies for advanced cases. Despite the potential advantages of PDT, such as tumor selectivity, minimization of systemic side effects and repeatability of treatment, some limitations still restrict its clinical application. Despite these challenges, its application in oral squamous cell carcinoma and oral potentially malignant disease is promising, both alone or in combination with other therapies. Addressing such pros and cons of this technique, PDT may then be a possible adjuvant tool in the management of OSCC.

Indexed as

cancer therapyhead and necknanomedicineoral squamous cell carcinomaphotodynamic therapy

Identifiers

PMID40589639
PMCPMC12206862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.